Circular RNA with Orna Therapeutics' Tom Barnes, Ph.D. and Advancing RNA's Anna Rose Welch

Business Of Biotech

We love to hear from our listeners. Send us a message.

As if Orna Therapeutics' CEO Thomas Barnes, CEO isn't a enough to draw you in to the Business of Biotech, we teamed up with Advancing RNA Editorial & Community Director Anna Rose Welch to co-host this week's episode. Together, Anna Rose and I press Dr. Barnes on his transition from academia to biotech, the therapeutic proposition of circular, or "O" RNA and why it holds great potential to best linear RNA constructs, the novel, platform- and partnership-based approaches Orna is taking to address B-cell lymphomas and Duchenne Muscular Dystrophy, viral vector and lipid nanoparticle complexity, and a whole lot more.

Register for Bioprocess Online’s Bio Expo Live, being held July 30th through August 1st . This inaugural expo is a fantastic opportunity for biopharma companies and contract manufacturers to evaluate the latest and greatest from the comfort of your desktop or mobile device. Conveniently, we’ve broken down the lineup into Upstream Solutions July 30th, Downstream Solutions July 31st, and Quality, Analytical, and Data Solutions August 1st. It’s absolutely free to register for this series of short, digestible, and interactive sessions -- just hit the links above to register for Bio Expo Live today!

Chapters

1. Circular RNA Biotech Innovations (00:00:00)

2. Innovations in RNA-based Gene Editing (00:07:59)

3. Advantages of Circular RNA in Biotech (00:13:59)

4. Innovating With Novel Technology Risks (00:22:22)

5. Emerging RNA Cell Therapy Potential (00:28:57)

6. RNA Platform Strategies and Partnerships (00:42:20)

7. Exploring the Future of RNA Therapies (00:48:49)